Russell Investments Group Ltd. Raises Holdings in ADMA Biologics Inc $ADMA

Key Points

• Russell Investments Group Ltd. increased its stake in ADMA Biologics by 152.7%, owning 1,632,675 shares valued at approximately $32.4 million as of its latest SEC filing.
• ADMA Biologics recently reported quarterly earnings of $0.15 EPS, exceeding analyst expectations and indicating a 13.8% increase in revenue year-over-year.
• Major institutional investors currently hold 75.68% of ADMA Biologics’ stock, reflecting significant institutional support for the company.

Russell Investments Group Ltd. boosted its holdings in ADMA Biologics Inc (NASDAQ:ADMA - Free Report) by 152.7% during the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 1,632,675 shares of the biotechnology company's stock after acquiring an additional 986,666 shares during the quarter. Russell Investments Group Ltd. owned 0.69% of ADMA Biologics worth $32,392,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also bought and sold shares of ADMA. Nuveen LLC bought a new stake in shares of ADMA Biologics during the 1st quarter valued at $93,543,000. B Group Inc. acquired a new stake in shares of ADMA Biologics during the fourth quarter worth about $39,231,000. Invesco Ltd. increased its holdings in ADMA Biologics by 13.9% in the 1st quarter. Invesco Ltd. now owns 12,866,904 shares of the biotechnology company's stock worth $255,279,000 after buying an additional 1,570,649 shares during the period. Raymond James Financial Inc. acquired a new stake in ADMA Biologics during the 4th quarter worth about $19,076,000. Finally, Dimensional Fund Advisors LP raised its stake in shares of ADMA Biologics by 16.0% during the 4th quarter. Dimensional Fund Advisors LP now owns 4,668,320 shares of the biotechnology company's stock valued at $80,065,000 after buying an additional 643,661 shares during the last quarter. 75.68% of the stock is currently owned by institutional investors.

ADMA Biologics Stock Down 0.4%

Shares of NASDAQ ADMA traded down $0.07 during midday trading on Tuesday, hitting $17.56. The company's stock had a trading volume of 712,396 shares, compared to its average volume of 3,136,547. The business's fifty day simple moving average is $18.22 and its two-hundred day simple moving average is $18.88. The firm has a market capitalization of $4.19 billion, a price-to-earnings ratio of 20.36 and a beta of 0.38. The company has a debt-to-equity ratio of 0.21, a current ratio of 5.33 and a quick ratio of 2.78. ADMA Biologics Inc has a 1 year low of $13.50 and a 1 year high of $25.67.

ADMA Biologics (NASDAQ:ADMA - Get Free Report) last posted its quarterly earnings data on Wednesday, August 6th. The biotechnology company reported $0.15 earnings per share for the quarter, topping analysts' consensus estimates of $0.14 by $0.01. ADMA Biologics had a return on equity of 41.01% and a net margin of 44.06%.The business had revenue of $121.98 million for the quarter, compared to analyst estimates of $121.77 million. During the same quarter in the prior year, the company earned $0.13 earnings per share. The company's revenue was up 13.8% on a year-over-year basis. On average, equities analysts predict that ADMA Biologics Inc will post 0.51 EPS for the current year.

Analyst Upgrades and Downgrades

ADMA has been the subject of a number of analyst reports. Raymond James Financial upped their price target on ADMA Biologics from $25.00 to $32.00 and gave the stock a "strong-buy" rating in a report on Thursday, May 8th. Wall Street Zen cut shares of ADMA Biologics from a "hold" rating to a "sell" rating in a research report on Friday, May 9th. One research analyst has rated the stock with a Strong Buy rating and two have given a Buy rating to the company's stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Buy" and an average price target of $27.67.

Insider Buying and Selling

In other ADMA Biologics news, Director Steve Elms sold 194,749 shares of ADMA Biologics stock in a transaction that occurred on Monday, June 16th. The stock was sold at an average price of $20.24, for a total value of $3,941,719.76. Following the sale, the director owned 87,330 shares of the company's stock, valued at approximately $1,767,559.20. The trade was a 69.04% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Jerrold B. Grossman sold 10,000 shares of the stock in a transaction that occurred on Monday, June 9th. The stock was sold at an average price of $21.31, for a total value of $213,100.00. Following the transaction, the director directly owned 478,194 shares of the company's stock, valued at approximately $10,190,314.14. This trade represents a 2.05% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 464,621 shares of company stock worth $9,644,269 over the last 90 days. 3.50% of the stock is owned by insiders.

ADMA Biologics Company Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.